Home > Drugs A – Z > Raltegravir (By mouth)

Raltegravir (By mouth)

Treats HIV infection.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Raltegravir is used together with other medicines for the treatment of the infection caused by human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is usually given to patients who have already received HIV medicines in the past. Raltegravir will not cure or prevent HIV infection or AIDS; however, it helps keep HIV from… Read more
Brand names include
Drug classes About this
Antiretroviral Agent

What works? Research summarized

Evidence reviews

Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison

OBJECTIVE: Compare the efficacy of 2 NRTIs combined with raltegravir (RAL), efavirenz (EFV), or protease inhibitors (PI) in the management of antiretroviral-naïve HIV adult patients.

Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials

OBJECTIVES: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the overall efficacy of new antiretroviral drugs, as well as the factors associated with increased efficacy. We compared CD4 cell count increases associated with chemokine (C-C motif) receptor 5 (CCR5) inhibitors or other new drugs, using indirect comparison.

Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis

BACKGROUND: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens. The purpose of this study was to review the evidence for integrase inhibitor use in clinical settings.

See all (5)

Summaries for consumers

Dolutegravir (Tivicay) for HIV infection: Dolutegravir for additional treatment in adults with HIV infection

In the spring of 2014 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed which advantages and disadvantages dolutegravir has compared with previous standard therapies in people who have already had medical treatment for HIV. One study was available to IQWiG for the purpose of this assessment. This study involved adults with HIV who had already had HIV therapy and were resistant to at least two HIV drugs.Participants in the study were divided into two groups. One group used dolutegravir, and the other was given the drug raltegravir. Both groups also received two additional drugs to treat HIV which were selected based on individual needs. A total of 724 people participated in this study and all data was analyzed after 48 weeks.

PubMed Health Blog...

read all...